Multiple myeloma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(15 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Multiple myeloma}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Multiple_myeloma]]
{{CMG}} {{AE}}{{HL}} {{shyam}}
{{CMG}} {{AE}} {{HMHJ}} {{HL}} {{shyam}}


==Overview==
==Overview==
Line 8: Line 8:
==Differentiating Multiple Myeloma from other Diseases==
==Differentiating Multiple Myeloma from other Diseases==


*The table below summarizes how to differentiate multiple myeloma from other conditions that have a similar presentation:<ref name="seer">{{Cite web  | last =  | first =  | title = Myeloma - SEER Stat Fact Sheets | url = http://seer.cancer.gov/statfacts/html/mulmy.html | publisher =  | date =  | accessdate = 17 February 2014 }}</ref>
*The table below summarizes how to differentiate multiple myeloma from other conditions that have a similar presentation:<ref name="seer">{{Cite web  | last =  | first =  | title = Myeloma - SEER Stat Fact Sheets | url = http://seer.cancer.gov/statfacts/html/mulmy.html | publisher =  | date =  | accessdate = 17 February 2014 }}</ref><ref name="pmid28934935">{{cite journal| author=Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J et al.| title=Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. | journal=BMC Musculoskelet Disord | year= 2017 | volume= 18 | issue= 1 | pages= 403 | pmid=28934935 | doi=10.1186/s12891-017-1756-1 | pmc=5609032 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28934935  }} </ref><ref name="pmid26401268">{{cite journal| author=Shaker JL, Albert C, Fritz J, Harris G| title=Recent developments in osteogenesis imperfecta. | journal=F1000Res | year= 2015 | volume= 4 | issue= F1000 Faculty Rev | pages= 681 | pmid=26401268 | doi=10.12688/f1000research.6398.1 | pmc=4566283 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26401268  }} </ref><ref name="pmid29299040">{{cite journal| author=Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN| title=The metabolism and significance of homocysteine in nutrition and health. | journal=Nutr Metab (Lond) | year= 2017 | volume= 14 | issue=  | pages= 78 | pmid=29299040 | doi=10.1186/s12986-017-0233-z | pmc=5741875 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29299040  }} </ref><ref name="pmid29128071">{{cite journal |vauthors=Soh KT, Tario JD, Wallace PK |title=Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry |journal=Clin. Lab. Med. |volume=37 |issue=4 |pages=821–853 |date=December 2017 |pmid=29128071 |pmc=5804349 |doi=10.1016/j.cll.2017.08.001 |url=}}</ref><ref name="pmid18971951">{{cite journal |vauthors=Kyle RA, Rajkumar SV |title=Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma |journal=Leukemia |volume=23 |issue=1 |pages=3–9 |date=January 2009 |pmid=18971951 |pmc=2627786 |doi=10.1038/leu.2008.291 |url=}}</ref><ref name="pmid25838344">{{cite journal |vauthors=Rajkumar SV, Landgren O, Mateos MV |title=Smoldering multiple myeloma |journal=Blood |volume=125 |issue=20 |pages=3069–75 |date=May 2015 |pmid=25838344 |pmc=4432003 |doi=10.1182/blood-2014-09-568899 |url=}}</ref>
{| align="center"
 
|-
{|
|
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center&quot;" "
| valign="top" |
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}}
Line 22: Line 18:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multiple myeloma]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multiple myeloma]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Chromosomal aberrations or other genetic insults
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*Malignant transformation of plasma cells
*[[Malignant]] transformation of [[plasma cells]]
*Clonal plasma cell proliferation
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diffuse [[bone]] pain and [[tenderness]] with [[osteolytic]] lesions
*Diffuse [[bone]] pain and [[tenderness]] with [[osteolytic]] lesions
*Renal failure
*[[Renal failure]]
*Hypercalcemia
*[[Hypercalcemia]]
*Anemia
*[[Anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Induction chemotherapy with bortezomib, lenalidomide, and dexamethasone
*Induction [[chemotherapy]] with [[bortezomib]], [[lenalidomide]], and [[dexamethasone]]
*Bisphosphonates
*[[Bisphosphonates]]
*RANK ligand inhibitors (denosumab)
*[[RANKL|RANK ligand]] inhibitors ([[denosumab]])
*Autologous stem cell transplantation
*[[Autologous bone marrow transplantation|Autologous stem cell transplantation]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Monoclonal gammopathy of undetermined significance]] ([[MGUS]])'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Asymptomatic]]
* [[Serum]] [[M protein]] of <30 g/L
* Fewer than 10% [[plasma cells]] in the [[bone marrow]]
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
*
| style="padding: 5px 5px; background: #F5F5F5;" |Observation
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Asymptomatic Plasma Cell Myeloma'''
('''Smoldering''' and '''Indolent plasma cell myeloma''')
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*[[Malignant]] transformation of [[plasma cells]]
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Asymptomatic]]
* [[Serum]] [[M protein]] of >30 g/L
* Greater than 10% [[plasma cells]] in the [[bone marrow]]
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
| style="padding: 5px 5px; background: #F5F5F5;" |Observation
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasma cell leukemia|Plasma Cell Leukemia]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
* [[Malignant]] transformation of [[plasma cells]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Renal failure]]
*[[Hypercalcemia]]
*[[Cytopenias]]
*No [[bone]] lesions
| style="padding: 5px 5px; background: #F5F5F5;" |[[Chemotherapy]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasmacytoma]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults
*[[Malignant]] transformation of [[plasma cells]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* Solitary bone [[plasmacytoma]] ([[bone]])
* Extramedullary [[plasmacytoma]] ([[Soft tissue|soft tissues]])
* Clinical manifestations related to [[tumor]] mass and compression [[symptoms]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Surgery]]
|-  
|-  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteoporosis]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteoporosis]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Imbalance between bone resorption and bone formation
*Imbalance between [[bone resorption]] and [[bone]] formation
*Preceded by osteopenia
*Preceded by [[osteopenia]]
*Decreased bone mineral density
*Decreased bone mineral density
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Acute musculoskletal pain if [[bone fractures|fractures]] develop
*Acute musculoskletal pain if [[bone fractures|fractures]] develop
*Severe decrease in [[bone mineral density|BMD]] on dual-energy X-ray absorptiometry (DEXA) test
*Severe decrease in [[bone mineral density|BMD]] on [[Dual energy X-ray absorptiometry|dual-energy X-ray absorptiometry]] ([[DEXA scan|DEXA]]) test
*T score less than -2.5 on DEXA scan
*T score less than -2.5 on [[DEXA scan|DEXA]] scan
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Calcium and vitamin D supplementation
*[[Calcium]] and [[vitamin D]] supplementation
*Bisphosphonates
*[[Bisphosphonate|Bisphosphonates]]
*Weight-bearing exercise
*Weight-bearing exercise
*Teriparatide
*[[Teriparatide]]
*RANK ligand inhibitors (denosumab)
*[[RANKL|RANK ligand]] inhibitors ([[denosumab]])
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteomalacia]]'''<ref name="pmid28934935">{{cite journal| author=Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J et al.| title=Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. | journal=BMC Musculoskelet Disord | year= 2017 | volume= 18 | issue= 1 | pages= 403 | pmid=28934935 | doi=10.1186/s12891-017-1756-1 | pmc=5609032 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28934935  }} </ref>
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteomalacia]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Inadequate mineralization of bone
*Inadequate [[mineralization of bone]]
*Deficiencies in vitamin D, calcium, or phosphorus
*Deficiency of [[vitamin D]] [[calcium]], or [[phosphorus]]
*Renal tubular acidosis
*[[Renal tubular acidosis]]
*Malabsorption
*[[Malabsorption]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diffuse [[bone]] pain, fatigue, and [[fractures]]
*Diffuse [[bone]] pain, fatigue, and [[fractures]]
Line 63: Line 105:
*[[Hypocalcemia]]
*[[Hypocalcemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Vitamin D3 supplementation
*[[Vitamin D3]] supplementation
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Scurvy]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Scurvy]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Vitamin C deficiency
*[[Vitamin C]] deficiency
*Malabsorption
*[[Malabsorption]]
*Hemodialysis
*[[Hemodialysis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Gum disease
*[[Gum disease]] such as gum [[bleeding]]
*Loose teeth
*Loose [[teeth]]
*Easy bruising
*Easy [[bruising]]
*Impaired [[immune]] response
*Impaired [[wound]] healing
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Vitamin C supplementation
*[[Vitamin C]] supplementation
*Citrus fruits
*Citrus fruits
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteogenesis imperfecta]]'''<ref name="pmid26401268">{{cite journal| author=Shaker JL, Albert C, Fritz J, Harris G| title=Recent developments in osteogenesis imperfecta. | journal=F1000Res | year= 2015 | volume= 4 | issue= F1000 Faculty Rev | pages= 681 | pmid=26401268 | doi=10.12688/f1000research.6398.1 | pmc=4566283 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26401268  }} </ref>
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteogenesis imperfecta]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Mutations in ''COL1A1'' or ''COL1A2''
*[[Mutations]] in ''[[COL1A1]]'' or ''[[COL1A2]]''
*Impaired type I collagen synthesis
*Impaired [[Type I collagen|type I collagen synthesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*[[Short stature]], [[scoliosis]], and propensity for [[Bone fracture|fractures]]
*[[Short stature]], [[scoliosis]], and propensity for [[Bone fracture|fractures]]
*Blue discoloration of sclera
*Blue discoloration of [[sclera]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Bisphosphonates
*[[Bisphosphonates]]
*Physical therapy
*[[Physical therapy]]
*Surgical fixation of brittle bones
*Surgical fixation of brittle [[bones]]
*Genetic counseling for offspring
*Genetic counseling for offspring
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Homocystinuria]]'''<ref name="pmid29299040">{{cite journal| author=Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN| title=The metabolism and significance of homocysteine in nutrition and health. | journal=Nutr Metab (Lond) | year= 2017 | volume= 14 | issue=  | pages= 78 | pmid=29299040 | doi=10.1186/s12986-017-0233-z | pmc=5741875 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29299040  }} </ref>
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Homocystinuria]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Deficiency of cystathione ''beta'' synthase
*Deficiency of [[Cystathionine-beta-synthase|cystathionine ''beta'' synthase]]
*Deficiency of folate, vitamin B12, or vitamin B6
*Deficiency of [[folate]], [[vitamin B12]], or [[vitamin B6]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Diffuse [[bone]] [[pain]] and [[musculoskeletal]] symptoms  
*Diffuse [[bone]] [[pain]] and [[musculoskeletal]] symptoms  
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*High-dose vitamin B6 supplementation
*High-dose [[vitamin B6]] supplementation
*Betaine supplementation
*[[Betaine]] supplementation
|}
|}
|}
==References==
==References==
{{reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
[[Category:Medicine]]
[[Category:Types of cancer]]
[[Category:Hematology]]
[[Category:Hematology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Neurosurgery]]
[[Category:Neurosurgery]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Surgery]]
[[Category:Differential diagnosis]]

Latest revision as of 22:46, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2] Haytham Allaham, M.D. [3] Shyam Patel [4]

Overview

Multiple myeloma must be differentiated from other causes of bone lesions such as osteoporosis, osteomalacia, scurvy, osteogenesis imperfecta, and homocystinuria. Each condition has unique causes, features, and treatment.

Differentiating Multiple Myeloma from other Diseases

  • The table below summarizes how to differentiate multiple myeloma from other conditions that have a similar presentation:[1][2][3][4][5][6][7]
Differential Diagnosis Causes Features Therapy
Multiple myeloma
Monoclonal gammopathy of undetermined significance (MGUS) Observation
Asymptomatic Plasma Cell Myeloma

(Smoldering and Indolent plasma cell myeloma)

Observation
Plasma Cell Leukemia Chemotherapy
Plasmacytoma Surgery
Osteoporosis
Osteomalacia
Scurvy
Osteogenesis imperfecta
Homocystinuria

References

  1. "Myeloma - SEER Stat Fact Sheets". Retrieved 17 February 2014.
  2. Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J; et al. (2017). "Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients". BMC Musculoskelet Disord. 18 (1): 403. doi:10.1186/s12891-017-1756-1. PMC 5609032. PMID 28934935.
  3. Shaker JL, Albert C, Fritz J, Harris G (2015). "Recent developments in osteogenesis imperfecta". F1000Res. 4 (F1000 Faculty Rev): 681. doi:10.12688/f1000research.6398.1. PMC 4566283. PMID 26401268.
  4. Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN (2017). "The metabolism and significance of homocysteine in nutrition and health". Nutr Metab (Lond). 14: 78. doi:10.1186/s12986-017-0233-z. PMC 5741875. PMID 29299040.
  5. Soh KT, Tario JD, Wallace PK (December 2017). "Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry". Clin. Lab. Med. 37 (4): 821–853. doi:10.1016/j.cll.2017.08.001. PMC 5804349. PMID 29128071.
  6. Kyle RA, Rajkumar SV (January 2009). "Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma". Leukemia. 23 (1): 3–9. doi:10.1038/leu.2008.291. PMC 2627786. PMID 18971951.
  7. Rajkumar SV, Landgren O, Mateos MV (May 2015). "Smoldering multiple myeloma". Blood. 125 (20): 3069–75. doi:10.1182/blood-2014-09-568899. PMC 4432003. PMID 25838344.